- Home
- SNY vs NTES Comparison
SNY vs NTES Comparison
Compare SNY & NTES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNY
- NTES
- Stock Information
- Founded
- SNY 1994
- NTES 1997
- Country
- SNY France
- NTES China
- Employees
- SNY N/A
- NTES N/A
- Industry
- SNY Biotechnology: Pharmaceutical Preparations
- NTES Computer Software: Prepackaged Software
- Sector
- SNY Health Care
- NTES Technology
- Exchange
- SNY Nasdaq
- NTES Nasdaq
- Market Cap
- SNY 116.1B
- NTES 95.1B
- IPO Year
- SNY N/A
- NTES 2000
- Fundamental
- Price
- SNY $49.11
- NTES $150.04
- Analyst Decision
- SNY Buy
- NTES Strong Buy
- Analyst Count
- SNY 4
- NTES 6
- Target Price
- SNY $61.50
- NTES $121.50
- AVG Volume (30 Days)
- SNY 3.9M
- NTES 628.6K
- Earning Date
- SNY 10-24-2025
- NTES 11-13-2025
- Dividend Yield
- SNY 3.25%
- NTES 1.93%
- EPS Growth
- SNY 118.56
- NTES 19.96
- EPS
- SNY 8.65
- NTES 1.49
- Revenue
- SNY $53,714,621,258.00
- NTES $15,310,016,889.00
- Revenue This Year
- SNY $1.53
- NTES $11.57
- Revenue Next Year
- SNY $7.06
- NTES $7.58
- P/E Ratio
- SNY $5.69
- NTES $100.69
- Revenue Growth
- SNY 15.65
- NTES 2.75
- 52 Week Low
- SNY $44.62
- NTES $75.88
- 52 Week High
- SNY $60.12
- NTES $159.55
- Technical
- Relative Strength Index (RSI)
- SNY 54.77
- NTES 54.25
- Support Level
- SNY $44.62
- NTES $149.21
- Resistance Level
- SNY $51.05
- NTES $154.41
- Average True Range (ATR)
- SNY 0.83
- NTES 2.64
- MACD
- SNY 0.43
- NTES -0.82
- Stochastic Oscillator
- SNY 68.73
- NTES 48.99
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
About NTES NetEase Inc.
Founded in the late 1990s as an internet portal, NetEase has transformed into a leading force in the second-largest online game company gaming in China. While its initial success was built upon the massively multiplayer online role-playing game Fantasy Westward Journey, NetEase has expanded its portfolio with captivating franchises that resonate with both domestic and international players. Over the past decade, the company has created titles such as Justice, Identity V, Naraka: Bladepoint, and Eggy Party, all of which maintain significant player bases today. Beyond in-house development, the company also collaborates with likes of Microsoft and Marvel to create and publish games based on renowned IPs, including World of Warcraft, Diablo Immortal, and Marvel Rivals.